ML-193

Research use only, not for human use.

ML-193 is a potent and selective GPR55 antagonist( IC50 : 221 nM).

ML-193 is a potent and selective GPR55 antagonist( IC50 : 221 nM). It shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2, and can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats.

ML-193 (0.01-100 μM; pretreated for 15 min) inhibits β-arrestin trafficking induced by L-α-lysophophosphatidylinositol (LPI, 10 μM) and ML186 (1 μM) with IC50s of 0.22 μM and 0.12 μM, respectively.ML-193 (0.01-10 μM; pretreated for 30 min) decreases the LPI-mediated ERK1/2 phosphorylation, with an IC50 of 0.2 μM in U2OS cells.ML-193 (5 μM; pretreated for 30 min) attenuates the GPR55 agonists induced increases in hNSCs proliferation rates.ML-193 (5 μM; 10 d) attenuates the ML184-induced increases in hNSCs differentiation.

ML193 (1 and 5 μg/rat; intra-striatal at a rate of 1 μL/min) attenuates sensorimotor deficits and slip steps, increases motor coordination in PD rats. Animal Model:Male Wistar rats (200-250 g) were induced experimental Parkinson by 6-hydroxydopamine (6-OHDA, 10 μg/rat)Dosage:1 and 5 μg/rat Administration:Injected into the right striatum at a rate of 1 μL/min Result:Increased the time on the rotarod, decreased latency to remove the label and slip steps in 6-OHDA-lesioned rats.

CID 1261822

GPCR/G Protein

Cannabinoid Receptor

GPR55

——

——

713121-80-3

527.59

C28H25N5O4S

>98% (HPLC)

In Vitro:?DMSO : 33.33 mg/mL (63.17 mM)

Cc1c(NS(c(cc2)ccc2NC(c2cc(-c3ncccc3)nc3c(C)cc(C)cc23)=O)(=O)=O)onc1C

——

(-20℃)

With Ice Pack

≥ 2 years